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Whole-genome  sequencing  and  analysis  of  tumor  and 
matched normal genomes with next-generation sequen-
cing  platforms  has  begun  to  illuminate  commonly 
mutated genes and transcript-level events that contribute 
to the underlying tumor biology. To elucidate the role of 
frequent  somatic  mutations,  the  mutant  proteins  have 
been biochemically characterized and the results inter-
preted in terms of the selective advantages these variants 
may  confer  on  the  tumor.  Certain  somatic  alterations 
have  demonstrable  prognostic  value  for  specific  tumor 
types  in  which  they  commonly  occur,  although  their 
down  stream metabolic signatures may obviate geno  typing 
to identify their mutational status. The metabolic signature 
is  a  direct  result  of  the  mutation’s  impact  on  a  given 
protein/enzyme;  therefore,  rather  than  performing 
sequencing  to  detect  whether  a  mutation  is  present, 
metabolic profiling may be more straightforward, cheaper, 
and have a lower error rate, for example. New insights into 
the  relationship  between  a  primary  tumor  and  its  fatal 
metastatic  disease  are  also  beginning  to  emerge  from 
genomic  comparisons,  with  the  fine  detail  afforded  by 
next-generation sequencing enabling these comparisons.
The transcriptomes of cancer cells also have their own 
unique  somatic  complexities,  which  often  result  from 
structural perturbations to the genome, but can be due to 
transcription-level  events  such  as  alternative  splicing, 
RNA  editing  or  transcript  fusion.  These  types  of 
alterations may explain certain aspects of tumor biology 
and may also be corroborated by cytogenetic phenomena. 
In this review, I will describe some tumor-specific altera-
tions  that  were  discovered  as  a  result  of  analyses  of 
unbiased  genome  or  transcriptome  sequencing  data 
(unbiased sequencing does not select for portions of the 
genome  or  transcriptome  in  advance,  and  the  entire 
genome or transcriptome is therefore surveyed) and then 
illustrate how these discoveries were pursued further to 
reveal  insights  into  tumor  biology  that  have  enhanced 
our clinical diagnosis of cancer and our concepts of how 
best to treat it.
Genome-based discovery in cancer
In  a  1956  paper  [1],  Otto  Warburg  observed  that  the 
predominant mode of energy production in cancer cells 
was  by  aerobic  glycolysis  rather  than  by  oxidation  of 
pyruvate in mitochondria, as in normal cells. This obser-
vation  led  Warburg  to  postulate  that  this  change  in 
metabolism  was  a  fundamental  cause  of  cancer.  Years 
later, in 1986, Renato Dulbecco opined that studying the 
cellular genome should be pursued to learn more about 
cancer, either by taking a ‘piecemeal’ approach of looking 
gene by gene, or by sequencing the whole genome [2].
Somatic mutations in the genes IDH1 and IDH2
In the current era of cancer genomics, one of the most 
interesting  and  unexpected  discoveries  to  result  from 
unbiased  sequencing  of  matched  tumor  and  normal 
samples  is  the  somatic  point  mutations  found  in  the 
genes for two isocitrate dehydrogenase isoenzymes, IDH1 
and IDH2. First discovered by sequencing the exome (the 
exons collectively) of the glial brain tumor glioblastoma 
multiforme (GBM) [3], mutated IDH1 was found in 12% 
of  tumors  analyzed.  The  general  approach  to  exome 
capture  and  analysis  is  shown  in  Figure  1.  Subsequent 
focused re-sequencing refined the occurrence of muta-
tions at arginine 132 (R132) of IDH1, which are found in 
more than 80% of secondary GBMs (GBMs that initially 
present  as  low-grade  astrocytomas  (tumors  of 
astrocytes)), and less than 10% of primary GBMs [4-6]. 
Subsequent work, explained later in this review, identified 
the  biological  impact  of  these  mutations  on  enzyme 
function. On examining gliomas, including GBMs, negative 
for  IDH1  mutations,  recurrent  somatic  muta  tions  of 
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Not only are the IDH1 and IDH2 mutations frequent, but 
studies by several laboratories have established that the 
mutation in IDH1 occurs early in glioma progression [8]. 
Notably, the mutations affect only one allele at the given 
locus (of the two alleles of either IDH1 or IDH2, but not 
both in the same tumor), which is puzzling considering 
the  evidence  that  they  are  selected  for  early  in  tumori-
genesis. Analysis of the correlation between mutation in 
IDH1 or IDH2 and various clinical features has revealed 
interesting asso  ciations between the presence of mutation 
and  an  early  age  of  disease  onset  and  overall  longer 
survival  time  in  GBMs  and  in  anaplastic  astrocytomas 
(another type of glial tumor, distinct from GBMs) [4].
Figure 1. General schema for targeted exome capture, whole genome sequencing, and transcriptome sequencing. (a) In exome capture, 
a random library of genomic fragments, each containing platform-specific adapters on each end, is combined with a set of probes that define 
the human exome. Following hybridization, the probe:genomic library fragment hybrids are captured using magnetic beads and isolated from 
solution by the application of a magnet, or by solid phase capture. Denaturing conditions are used to elute the captured genomic library fragment 
population from the hybrids, and prepared for sequencing. (b) In whole genome sequencing, the same random fragment library is constructed as 
in (a), but the resulting fragments are sequenced directly without a capture step. (c) In transcriptome sequencing, the RNA is converted to cDNA, 
the resulting cDNAs are fragmented, and the library adapters are ligated to the resulting fragments, followed by sequencing. Panel (a) reproduced 
with permission from [27].
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lism,  catalyzing  the  conversion  of  isocitrate  to  α-keto-
glutarate (α-KG) and generating NADPH from NADP+ in 
the process (Figure 2). The crystal structure of IDH1 [9] 
predicts that the amino acid substitutions found at the 
R132 position will impair the interaction of the enzyme 
with  its  isocitrate  substrate,  and  functional  and  bio-
chemical studies of the mutant proteins by several groups 
have provided critical insights into this [4,10,11]. Zhao 
and  colleagues  [10]  evaluated  the  in  vitro  enzymatic 
activities of three tumor-derived IDH1 mutants - R132H, 
R132C and R132S - by expressing mutant constructs in 
transformed human embryonic kidney 293T cells. They 
observed  all  three  mutants  to  have  a  more  than  80% 
reduction  in  the  ability  to  convert  isocitrate  to  α-KG 
compared with the wild-type enzyme, and further kinetic 
analyses  revealed  a  dramatically  reduced  affinity  for 
isocitrate in all three mutants. As IDH1 functions as a 
homodimeric  complex,  Zhao  et  al.  [10]  isolated  IDH1 
dimers expressed from the R132H mutant and wild-type 
genes  introduced  into  Escherichia  coli.  Three  dimer 
combinations  were  identified,  the  wild-type:R132H 
heterodimer  exhibited  only  4%  of  the  wild-type  dimer 
enzyme activity, while R132H:R132H homodimers were 
almost completely inactive.
What are the metabolic consequences of IDH1 muta-
tions? Using the U-87MG human glioblastoma cell line, 
Zhao et al. [10] demonstrated a concomitant reduction in 
Figure 2. Impact of IDH1/2 mutations on tumor cell biology. (a) In normal cells, the role of IDH1 and IDH2 enzymes is to convert isocitrate 
to α-ketoglutarate (α-KG), converting NADP+ to NADPH. The presence of α-KG regulates prolylhydroxylases (PHD) that, in turn, promote the 
degradation of hypoxia-inducible factor 1α (HIF-1α). HIF-1α is a transcription factor that regulates the expression of genes related to glucose 
metabolism, angiogenesis, and other signaling pathways by sensing low cellular oxygen levels. The mutant IDH enzymes convert α-KG to 
2-hydroxyglutarate (2-HG), leading to the build up of this oncometabolite. (b) Comparison of metabolomic profiling of IDH wild-type (upper panel) 
and mutant (lower panel) cells, indicating the increased levels of 2-HG associated with the mutation. 2-HG is absent in IDH wild-type cells. Panel (b) 
reproduced with permission from [15].
NADP
NADP
NADPH
NADPH
(a) (b)
IDH1
IDH2
IDH2 R172K / R140Q
AML with IDH2
AML with IDH2 R140Q
α-KG
)
Isocitrate
2-HG
PHD
α-KG
OH -
H
y
d
r
o
x
y
l
a
t
i
o
n
D
e
g
r
a
d
a
t
i
o
n
HIF-1α
Glucose metabolism
associated genes
Angiogenesis
associated genes
1.00
0.80
0.60
0.40
0.20
0
30.5 31.0 31.5 32.0 32.5 33.0 33.5 34.0
Asp
Glu
M
e
t
a
b
o
l
i
t
e
 
a
b
u
n
d
a
n
c
e
M
e
t
a
b
o
l
i
t
e
 
a
b
u
n
d
a
n
c
e
Elution time (min)
1.00
0.80
0.60
0.40
0.20
0
30.5 31.0 31.5 32.0 32.5 33.0 33.5 34.0
Asp
Glu
Elution time (min)
2HG
IDH1 R132 H/C/S
+
+
Mardis Genome Biology 2010, 11:211 
http://genomebiology.com/2010/11/5/211
Page 3 of 8cellular  α-KG  levels  after  knocking  down  endogenous 
IDH1, and because α-KG is required by prolyl  hydroxy-
lases, enzymes that hydroxylate and promote the degra-
dation of hypoxia-inducible factor 1α (HIF-1α), the intra-
cellular levels of HIF-1α were also characterized. Zhao et 
al. showed that when wild-type IDH1 is knocked down 
by RNA interference using short hairpin RNA, HIF-1α is 
elevated, and when IDH1 is overexpressed, HIF-1α levels 
are  reduced.  HIF-1α  is  a  component  of  HIF-1,  a 
transcription factor that regulates the expression of genes 
related to glucose metabolism, angiogenesis, and other 
signaling pathways by sensing low cellular oxygen levels. 
By performing quantitative PCR to measure the trans-
cripts  of  three  known  HIF-1  target  genes  -  glucose 
transporter 1 (Glut1), vascular endothelial growth factor 
(VEGF), and phosphoglycerate kinase (PGK1) - Zhao et 
al. demonstrated induced expression of these genes as a 
consequence of either the knockdown of wild-type IDH1 
or  the  expression  of  the  IDH1  R132H  mutant.  On 
staining glioma samples for HIF-1α, those tumors with 
previously  identified  R132H  mutations  showed  a 
statistically stronger staining signal than those without 
mutations. Thus, this body of evidence has demonstrated 
that when IDH1 is mutated, its function is reduced and 
the  downstream  impact  of  that  reduced  function  (the 
consequential upregulation of HIF-1α) contributes to the 
cell’s  progression  to  cancer,  thereby  indicating  that  a 
likely  function  of  IDH1  is  that  of  a  tumor  suppressor 
gene. Further experimentation is needed to support the 
claim that IDH2 may be a tumor suppressor gene also.
Building on the initial characterizations of IDH1 muta-
tions in gliomas, Dang et al. [11] took a metabolomics-
based approach to identify further changes in associated 
metabolite levels when an IDH1 mutation is present [11]. 
They  found  2-hydroxyglutarate  (2-HG)  to  be  the  only 
metabolite with significantly increased abundance in cells 
expressing  R132H  mutant  IDH1.  In  a  clever  series  of 
experiments, the increase in 2-HG was shown to result 
from  the  NADPH-dependent  reduction  of  α-KG  by 
mutant  IDH1,  a  new  function  that  is  enabled  by  the 
mutation at R132. The authors demonstrated a similar 
gain of function for the R132C, R132L and R132S muta-
tions. Their X-ray crystallographic studies showed that 
the R132H mutation in IDH1 results in the formation of 
an active site distinct from that of the wild-type enzyme. 
With the aim of improving diagnostic efficacy, Dang et al. 
examined 12 GBM tumors with various R132 mutations 
in IDH1, and found 2-HG levels 100-fold greater or more 
than  in  tumors  with  wild-type  IDH1;  the  measured 
decrease in α-KG was, however, not statistically different 
in  mutant  versus  wild-type  IDH1  tumors.  This  finding 
indicates  that  in  the  clinic,  detecting  patients  with 
increased 2-HG levels would identify GBMs with IDH1 
mutations,  predicting  an  overall  longer  survival  time. 
Indeed, since secondary GBMs develop from lower-grade 
gliomas,  therapeutic  inhibition  of  2-HG  production 
might  slow  the  transition  time  to  GBM  development, 
offering an improved survival benefit as a result.
In our laboratory we have been using a whole-genome 
shotgun  approach  to  sequence  tumor  genomes.  In  the 
second  case  of  acute  myeloid  leukemia  (AML)  we 
sequenced,  we  discovered  an  IDH1  R132  mutation  that 
was subsequently found in about 8% of our 187 banked 
AML patient samples, showing that this mutation is not 
restricted  to  gliomas  [12].  In  these  tumor  genomes,  we 
detected  R132C,  R132H  and  R132S  substitutions,  with 
R132C being most common (8 of 16). PCR assays designed 
to detect IDH2 R172 mutations in the 188 AML samples 
did not reveal any. Correlation analyses of clinical data and 
mutational status for AML patients with IDH1 mutations 
indicated that the presence of IDH1 mutations, in cases 
with  normal  cytogenetics  and  with  wild-type  nucleo-
phosmin-1 (NPM1), a commonly mutated gene in AML 
that has been known for some time, predicted a worse 
prognosis,  although  we  did  not  reach  statistical 
significance with our cohort. Soon after, Schnittger et al. 
[13] reported an analysis of a cohort of 999 AML patients, 
finding that IDH1 mutations were frequent (in 9.3% of 
samples), that the R132C mutant was the most common, 
and that in the presence of wild-type NPM1 and inter-
mediate  cytogenetics  (a  cytogenetic  evaluation  of  the 
leukemia  cells  revealing  no  clues  as  to  the  patient’s 
prognosis), patients with IDH1 mutations had a signifi-
cantly unfavorable prognosis (P = 0.038).
A subsequent study by Gross et al. [14] examined an 
additional 145 AML biopsies, identifying 11 IDH1 R132 
mutant  samples  [14].  Four  IDH1-mutant  primary 
samples had relapse samples that also carried the IDH1 
mutation. AML cells carrying the R132 mutant of IDH1 
were found by gas chromatography-mass spectrometry 
to  have  2-HG  levels  around  50-fold  greater  than  in 
samples  with  wild-type  IDH1.  Similarly,  higher  2-HG 
levels were detected in sera from patients positive for the 
IDH1 R132 mutation. Two wild-type IDH1 samples had 
elevated 2-HG levels and were found to be carrying IDH2 
R172  mutations,  the  first  report  of  these  in  AML. 
Importantly, this paper reinforced the fact that metabolite 
screening  rather  than  mutational  screening  can  be  an 
important  diagnostic  approach  for  the  detection  of 
elevated  2-HG  levels  and,  by  inference,  IDH1/2 
mutations.  Because  of  the  apparent  predominance  in 
AML of the IDH1 R132C mutation over R132H (which is 
more predominant in gliomas), Gross et al. [14] looked at 
the kinetics of the R132C mutant enzyme. The R132C 
enzyme showed a dramatic loss of affinity for isocitrate 
(resulting in a reduction in KM) and a drop of more than 
six  orders  of  magnitude  in  net  efficiency  (Kcat/KM)  of 
isocitrate metabolism.
Mardis Genome Biology 2010, 11:211 
http://genomebiology.com/2010/11/5/211
Page 4 of 8In  another  recent  study,  our  understanding  of  IDH 
mutations and their detection has been extended. Ward 
et al. [15] have determined that the gain of function seen 
in the IDH1 R132 mutants (that is, the ability to reduce 
α-KG)  is  also  found  in  the  IDH2  R172K  mutant. 
Metabolic  profiling  of  cells  expressing  IDH2  R172K 
revealed  an  approximately  100-fold  increase  in  intra-
cellular 2-HG compared with cells overexpressing wild-
type IDH2, and this finding was extended to leukemia 
cells carrying the IDH2 R172K mutation. Ward et al. [15] 
also  screened  AML  samples  with  normal  cytogenetics 
but unknown IDH mutational status for increased levels 
of 2-HG, and then evaluated the mutational status based 
on the result of the screening assay. In this test, 2-HG 
measurement  was  found  to  predict  mutational  status 
with high accuracy. In addition, a new IDH2 mutation, 
R140Q,  was  identified  in  five  samples.  In  a  second 
evaluation of 78 AML samples, IDH2 R140Q mutations 
were found to be more frequent than either IDH1 R132 
mutations or IDH2 R172K [15].
Despite some differences among sample sets, this body 
of  work,  aiming  to  characterize  the  impact  of  IDH 
mutations on tumor cell biology has led to the conclusion 
that  all  mutations  discovered  so  far  enable  a  gain  of 
function in α-KG reduction with a concomitant increase 
in the tumor-specific metabolite, or oncometabolite, 2-
HG. Although the contribution of 2-HG to tumor cell 
biology remains speculative, Ward et al. noted that all 
IDH mutation-containing tumor types identified so far 
(leukemias and gliomas) are distinguished by prolifera-
tion of a relatively undifferentiated cell popula  tion, and in 
this  context  the  effect  of  2-HG  in  the  tumor  and  its 
microenvironment is to block cellular differentiation [15].
Whole-genome comparisons of matched primary 
and metastatic cancers
One  intriguing  aspect  of  cancer  genomics,  for  which 
published examples are few, involves comparing genome-
wide  alterations  between  the  matched  primary  and 
metastatic cancer genomes from the same patient as a 
way of elucidating both their inter-relationships and the 
metastatic process. The first such study, by Shah et al. 
[16],  focused  whole-genome  and  whole-transcriptome 
sequencing  on  a  metastatic  tumor  genome  from  an 
estrogen-receptor-positive, invasive lobular breast cancer 
that occurred 9 years after the patient’s initial diagnosis 
and  treatment.  After  a  combined  analysis  to  identify 
somatic  mutations  in  both  the  genomic  and  trans-
criptomic data, the primary tumor taken 9 years earlier 
and the matched blood normal genomes were queried in 
the  light  of  these  findings.  The  aim  was  to  search  the 
primary  tumor  genome  for  the  30  mutations  that  had 
been  found  and  validated  as  tumor-associated  in  the 
metastatic  genome,  and  to  establish  the  somatic  or 
germline  nature  of  the  variants  by  comparing  their 
occurrence in blood cells. Variants that were found in the 
primary tumor data were deeply sampled by sequencing 
to  provide  an  estimate  of  the  allele  frequency  for  the 
somatic mutation in the primary tumor. Because of the 
9-year interval between diagnosis of the primary tumor 
and metastasis, significant differences in mutational load 
were  present;  only  3  of  the  28  tested  mutations  were 
prevalent  in  the  primary  cancer  cells,  6  had  an  allele 
frequency of 1 to 13%, and 19 were not detected and were 
therefore  metastasis-specific.  Genes  found  in  this 
analysis to have somatic point mutations were tested for 
frequency of mutation in 192 breast cancers, revealing 
that both the gene for the receptor kinase HER2 (3 of 
192) and for the HAUS augmin-like complex, subunit 3 
(HAUS3);  2  of  192)  were  mutated  [16].  A  second 
interesting finding from this study was the detection of 
two  nonsynonymous  variants  that  were  introduced  by 
RNA  editing,  perhaps  the  first  description  of  this 
phenomenon from next-generation sequencing data and 
a strong testament to the importance of transcriptomic 
data in broadening the range of variant discovery from 
cancer genomics.
A recent study by our laboratory used next-generation 
whole-genome resequencing, analysis and comparison of 
the genomes of a matched primary breast tumor, meta-
static brain tumor, and blood normal from an African-
American patient with basal subtype breast cancer [17] 
This  estrogen-receptor-negative  tumor  represents  one 
the most aggressive types of breast cancer, and in this 
patient only 8 months elapsed between diagnosis of the 
primary tumor and a diagnosis of metastatic disease. We 
also  sequenced  the  genome  of  a  human-in-mouse 
xenograft  [18]  passage  of  the  patient’s  primary  tumor, 
taken  by  core  biopsy  procedure  before  adjuvant 
chemotherapy  and  placed  into  the  fat  pad  of  a  NOD/
SCID  female  mouse.  Briefly,  we  found  48  mutations 
shared across all 3 tumors, and only 2 metastasis-specific 
point  mutations.  Two  mutations,  identified  in  this 
analysis,  in  the  kinase  JAK2  (affecting  the  JAK-STAT 
signaling pathway) and in the gene CSMD1 (CUB and 
Sushi multiple domains 1; loss of CSMD1 expression is 
associated  with  poor  survival  in  invasive  ductal  breast 
carcinoma [19]) were also found mutated in other types 
of  breast  cancer  samples.  Interestingly,  we  established 
that the frequency of 16 mutations in the primary tumor 
cell population was lower than 10% but rose to very high 
frequency in both the metastatic and xenograft samples.
In addition to point mutations, 7 inter-chromosomal 
translocations, 6 inversions and 28 large deletion events 
were detected and validated as tumor-associated. One of 
the large deletions was particularly interesting, and nicely 
illustrates  the  exquisite  resolution  afforded  by  next-
generation  sequencing  as  well  as  emphasizing  the 
Mardis Genome Biology 2010, 11:211 
http://genomebiology.com/2010/11/5/211
Page 5 of 8impor  tant  role  of  large  structural  rearrangements  in 
tumor  biology.  A  large  (more  than  500  kb)  biallelic 
deletion,  shown  in  Figure  3,  was  detected  by  the 
BreakDancer  algorithm  [20],  which  identifies  read  pair 
sequences  that  map  to  the  reference  genome  at  an 
unexpected  distance  or  orientation  relative  to  one 
another, and hence identifies a putative site of structural 
variation.  The  assembly  of  paired  reads  defining  the 
deleted  region  resulted  in  two  contigs  with  distinctly 
different breakpoints, both of which were confirmed by 
PCR and sequencing. Annotation of the region indicated 
that the gene CTNNA1 was completely deleted on both 
alleles. CTNNA1 encodes an α-catenin, loss of which has 
been  shown  to  lead  to  global  loss  of  cell  adhesion  in 
human breast cancer cells [21]. Figure 3 shows that there 
are an increasing number of cells containing the bi-allelic 
deletion  in  the  transition  from  primary  to  metastatic 
disease, and that the xenograft tumor cells carry only the 
bi-allelic deletion in their genomes - trends reminiscent 
of the somatic point mutations mentioned in the previous 
paragraph.
Monitoring tumor-specific DNA biomarkers
At  the  interface  between  variant  discovery  and  the 
transition  from  primary  to  metastatic  disease  lies  the 
possibility  of  identifying  personalized  biomarkers  that 
might enable an oncologist to monitor the progression or 
remission of a cancer. This approach has been elegantly 
developed by Leary et al. [22], who utilized long-distance 
mate-pair  sequencing  (a  variation  of  paired  end 
sequencing  involving  circularization  of  long  DNA 
fragments  (>1  kb)  and  ligation  to  an  internal  adapter 
DNA of known sequence) of an approximately 1.4 kbp 
region on the SOLiD platform to detect and characterize 
tumor-specific structural variations in two colon and two 
breast tumors [22]. Each sample was found to carry at 
least  four  validated  somatic  rearrangements  that  were 
then used to design PCR assays by which they could be 
detected.  Patients’  sera  were  assayed  by  PCR  and  this 
revealed that the amount of DNA circulating in plasma 
was sufficient to detect the tumor DNA rearrangements. 
In one case, serum samples were taken before and after 
tumor  resection,  and  the  levels  of  tumor-specific  bio-
marker DNA in the plasma mirrored these proce  dures. 
This  remarkable  demonstration  may  transform  our 
clinical approach to monitoring the course of cancer with 
minimally invasive methods.
Transcriptome-based discovery in cancer
Novel fusion transcripts in prostate tumors
Several groups now have pioneered efforts at unbiased 
transcriptome  discovery  using  next-generation  sequen-
cing of mRNA (RNA-seq) from the tumor cell population 
and a variety of approaches to analyze the data. Although 
algorithmically complex to detect, there are a number of 
unique  transcription-level  processes  that  modify  the 
Figure 3. Two overlapping CTNNA1 deletions on chromosome 5 
in three tumors. A graph of sequence depths, read pairs and genes 
in a 638,468-bp region containing two overlapping deletions. The 
top four panels display the read depths at each base, and the reads 
within the region whose mates mapped at an abnormal distance 
are displayed as bars, with matched pairs connected by arcs. Two 
different shades of blue indicate the two separate allelic deletion 
events (538,467 bp and 515,465 bp in length). The bottom panel 
displays genes annotated in this genomic region. Reproduced with 
permission from [17].
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editing, and the formation of chimeric transcripts. Maher 
et al. have published two studies [23,24] that illustrate the 
development and implementation of RNA-seq analytical 
approaches  to  discover  novel  fusion  transcripts  in 
prostate tumors, which are often regulated by androgen 
levels. Initially, a dual-platform strategy combined longer 
read-length RNA-seq data from the Roche/454 platform 
with shorter RNA-seq fragment reads from the Illumina 
platform,  and  resulted  in  the  discovery  of  a  novel 
chimeric  transcript,  SLC45A3-ELK4,  in  prostate  tumor 
samples [23]. The second approach [24] took advantage 
of  Illumina  paired-end  RNA-seq  data  and  a  different 
algorithmic filtering of mapped paired ends to identify 
putative  chimeric  transcripts.  When  combining  these 
read  pairs  with  unmapped  reads  that  span  the  fusion 
boundary,  fusion  transcripts  previously  identified  in 
prostate  cancer  cells,  such  as  TMPRSS2-ERG,  were 
detected,  as  were  novel  fusion  transcripts  such  as 
HERPUD1-ERG. These discoveries not only enhance our 
understanding of fusion transcripts in cancer, but have 
led to experiments to interrogate the role of hormonal 
signaling  by  androgens  in  inducing  chromosomal 
movements  that  bring  two  genes  that  participate  in  a 
detected fusion event into close proximity [25].
FOXL2 mutations in granulosa-cell ovarian tumors
In a recent study, Shah et al. [26] evaluated the trans-
criptomes of four adult granulosa-cell tumors (GCTs) of 
the  ovary,  identifying  putative  variants  involved  in 
tumorigenesis by shared analysis of all four tumors. A 
single missense point mutation in FOXL2 was identified 
(C134W), and was subsequently found in an additional 
86  out  of  89  cases  of  adult  GCTs.  The  gene  was  not 
mutated in other ovarian tumors of different types, nor in 
breast cancers that were tested. FOXL2 is a transcription 
factor  in  the  forkhead-winged-helix  family  and  is 
required for the normal development of granulosa cells. 
Although  loss-of-function  mutations  in  FOXL2  have 
been described for germline genomes, this was the first 
description  of  FOXL2  somatic  mutations  in  ovarian 
tumors. We await the results of downstream functional 
studies, which will be required to reveal the impact of the 
cysteine-to-tryptophan amino acid change on the activity 
of this transcription factor, as well as altered transcription 
of genes bound by FOXL2.
In  conclusion,  cancer  genomics,  largely  due  to  the 
unbiased and comprehensive nature of data that can be 
produced  by  next-generation  sequencing  platforms,  is 
being  applied  to  unravel  the  DNA-  and  RNA-level 
somatic  alterations  that  determine  tumor  development 
and  progression.  It  has  been  remarkable  to  see  the 
pursuit  of  enzymatic,  biochemical,  functional  and 
diagnostic  implications  of  the  earliest  discoveries 
afforded  by  these  methods.  Hopefully,  these  important 
efforts  will  scale  to  accommodate  the  wave  of  next-
generation-based  discovery  that  is  imminent,  and  the 
ultimate benefactors of our enhanced knowledge will be the 
patients and families whose lives are touched by this disease.
Published: 5 May 2010
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